Why the study?
Fat-poor angiomyolipoma has undetectable levels of fat and is often misdiagnosed as renal cell carcinoma.
Does a multichannel deep learning model based on unenhanced CT images accurately differentiate fat-poor angiomyolipoma from renal cell carcinoma in patients with solid renal masses?
Does a multichannel deep learning model based on unenhanced CT images accurately differentiate fat-poor angiomyolipoma from renal cell carcinoma in patients with solid renal masses?
A multichannel deep learning model using unenhanced whole-tumor CT images can accurately differentiate fat-poor angiomyolipoma from renal cell carcinoma, potentially reducing unnecessary radical nephrectomies.
Multichannel DL model may aid fp-AML vs RCC differentiation on imaging; leaves open prospective validation before clinical adoption.
PURPOSE: There are undetectable levels of fat in fat-poor angiomyolipoma. Thus, it is often misdiagnosed as renal cell carcinoma. We aimed to develop and evaluate a multichannel deep learning model for differentiating fat-poor angiomyolipoma (fp-AML) from renal cell carcinoma (RCC). METHODS: This two-center retrospective study included 320 patients from the First Affiliated Hospital of Sun Yat-Sen University (FAHSYSU) and 132 patients from the Sun Yat-Sen University Cancer Center (SYSUCC). Data from patients at FAHSYSU were divided into a development dataset (n = 267) and a hold-out dataset (n = 53). The development dataset was used to obtain the optimal combination of CT modality and input channel. The hold-out dataset and SYSUCC dataset were used for independent internal and external validation, respectively. RESULTS: In the development phase, models trained on unenhanced CT images performed significantly better than those trained on enhanced CT images based on the fivefold cross-validation. The best patient-level performance, with an average area under the receiver operating characteristic curve (AUC) of 0.951 ± 0.026 (mean ± SD), was achieved using the "unenhanced CT and 7-channel" model, which was finally selected as the optimal model. In the independent internal and external validation, AUCs of 0.966 (95% CI 0.919-1.000) and 0.898 (95% CI 0.824-0.972), respectively, were obtained using the optimal model. In addition, the performance of this model was better on large tumors (≥ 40 mm) in both internal and external validation. CONCLUSION: The promising results suggest that our multichannel deep learning classifier based on unenhanced whole-tumor CT images is a highly useful tool for differentiating fp-AML from RCC.
No takes yet. Share an insight, caveat, or question.
Yao et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: